Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
Renal cell carcinoma - sunitinib: assessment report
Overview
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: consultee and commentator comments on the assessment report
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: non-manufacturer submission
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: manufacturer submissions (executive summary only)
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: expert written personal statements